Navigation Links
Pharmacyclics Reports Second Quarter 2014 Results
Date:7/31/2014

ndamustine and rituximab versus placebo in combination with bendamustine and rituximab (BR) in R/R CLL/SLL patients who have received at least one line of prior therapy. The primary objective of the study is to demonstrate a clinically significant improvement in PFS when compared to bendamustine and rituximab. This study completed enrollment of 578 patients worldwide in Q1 of 2014. A data readout is anticipated in the first half of 2015.
  • BRILLIANCE (CLL3002): Phase III study of IMBRUVICA versus rituximab in patients with R/R CLL/SLL was initiated in the fourth quarter of 2013. This is a randomized, open-label, multi-center study to evaluate the efficacy and safety of versus rituximab in adult Chinese patients with R/R CLL or SLL with active disease requiring treatment, who have failed at least one prior line of therapy and are not considered appropriate candidates for treatment or retreatment with purine analog-based therapy or combination chemo-immunotherapy. The primary objective of the study is to demonstrate a clinically significant improvement in PFS. The enrollment target of this study is 150 patients.
  • Third-party sponsored: Phase III study of IMBRUVICA versus IMBRUVICA + rituximab versus bendamustine + rituximab in frontline newly diagnosed elderly (≥ 65 Years of Age) CLL/SLL patients (Alliance A041202) was initiated by the National Cancer Institute in the fourth quarter of 2013. This is a randomized, multi-center study designed to evaluate the improvement in PFS of IMBRUVICA with or without rituximab vs bendamustine and rituximab. Secondary outcome measures include overall survival and duration of response. The enrollment target of this multi-center study is 523 patients, enrollment initiated during the first quarter 2014.
  • Third-party sponsored: Phase III study in treatment-naive, young fit patients with CLL, comparing the combination of IMBRUVICA and Rituxan to chemo immunotherapy of FCR (fludarabine, cyclophosphamide, an
    '/>"/>

  • SOURCE Pharmacyclics, Inc.
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

    Related medicine technology :

    1. Pharmacyclics Announces Date of Conference call to discuss Financial Results for Second Quarter of 2014
    2. Pharmacyclics Announces Data Presentations for Ibrutinib in B-Cell Malignancies
    3. WuXi PharmaTech to Partner with Pharmacyclics
    4. Pharmacyclics Reports Third Quarter 2013 Results
    5. Pharmacyclics Announces Date of Conference call to discuss Financial Results for Third Quarter Ended September 30, 2013
    6. Pharmacyclics Reports Second Quarter 2013 Results
    7. Pharmacyclics Announces Date of Financial Results for Second Quarter Ended June 30, 2013 and Conference Call
    8. Pharmacyclics Reports First Quarter 2013 Results
    9. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
    10. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
    11. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/30/2015)... 30, 2015  Amgen (NASDAQ: AMGN ) ... of 2015. Key results include: , Total ... of 2014 to $5,370 million, with 6 percent ... (etanercept), Prolia ® (denosumab), Sensipar ® ... ® (denosumab). Unfavorable changes in foreign exchange ...
    (Date:7/30/2015)... -- Tianyin Pharmaceutical Inc. (NYSE Amex: TPI ) ... patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics ... notice it received on May 21, 2015 from the ... was below certain of the Exchange,s continued listing standards, ... the NYSE MKT Company Guide, due to the delay ...
    (Date:7/30/2015)... -- Growth of the U.S. nonprescription market is primarily driven ... to the OTC market. Due to an increasingly favorable ... activity over the next five years with several all ... entering the market into existing categories. If ... those with low to moderate likelihood), the market is ...
    Breaking Medicine Technology:Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 3
    ... Central Admixture Pharmacy Services, Inc. (CAPS®) , a ... service for the admixture and delivery of Hibernation Therapeutics, patented Adenocaine™ microplegia, ... , , ... , , ...
    ... Ampio Pharmaceuticals, Inc. (OTC Bulletin Board: AMPE), today announced that ... Biosciences, Inc. , , , ... will give AMPIO access to all rights, royalties and patents associated with ... pharmaceutical company after demonstrating safety and efficacy in a Phase II clinical ...
    Cached Medicine Technology:New Microplegia Service: World's First Low-Potassium, Non-Depolarizing Cardioplegia Available Exclusively from CAPS(R) 2New Microplegia Service: World's First Low-Potassium, Non-Depolarizing Cardioplegia Available Exclusively from CAPS(R) 3New Microplegia Service: World's First Low-Potassium, Non-Depolarizing Cardioplegia Available Exclusively from CAPS(R) 4Ampio Pharmaceuticals to Acquire DMI Biosciences, Inc. 2Ampio Pharmaceuticals to Acquire DMI Biosciences, Inc. 3
    (Date:7/31/2015)... ... 31, 2015 , ... Recently touted by Becker’s Healthcare as ... analytics , Jvion continues to disrupt the predictive analytic and big data market ... and population level illness to drive prevention and better health outcomes. Most recently, ...
    (Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... There’s no ... possible, even when it comes time to cook the next meal, making July the ... July by practicing best grilling tips and recipes. , Make the next cookout different ...
    (Date:7/31/2015)... ... ... M3 USA MDLinx.com, source of the Smartest Doc Board Exam Prep in ... The additions of Gastroenterology, Pulmonology and Allergy/Immunology round out an already robust selection of ... easy and painless. MDLinx offers thousands of board-exam style questions and exam-specific content ...
    (Date:7/31/2015)... Las Vegas, NV (PRWEB) , ... July 31, 2015 , ... ... Vegas bakery is now offering wedding cakes with custom designs, making life ... hard to deliver beautifully designed wedding cakes for each customer who orders one. , ...
    (Date:7/31/2015)... ... July 31, 2015 , ... The ... to patients and family members, medical professionals, and researchers, covering a variety of ... conference is a collaborative effort between the Mesothelioma Applied Research Foundation and Memorial ...
    Breaking Medicine News(10 mins):Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 3Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 3Health News:Pastry Palace of Las Vegas Announces It Is Now Offering Custom Wedding Cakes in Las Vegas 2Health News:New York Area Mesothelioma Specialists to Present at Conference 2Health News:New York Area Mesothelioma Specialists to Present at Conference 3
    ... really stink. And that could be the key to ... simple method to identify infectious bacteria by smell using ... sensor. Led by University of Illinois chemistry professor Ken ... Journal of the American Chemical Society . Hospitals ...
    ... Researchers in New York City say they are the first ... cells. A team at Albert Einstein College of Medicine ... gene transcription in living yeast cells, they say. Transcription occurs ... messenger RNA (mRNA) that then make the protein coded by ...
    ... Reporter , TUESDAY, April 26 (HealthDay News) -- Every ... worries about the food her daughter might choose to eat. ... a small amount of a peanut-containing food could cause a ... now that she,s a teenager and is eating out with ...
    ... and rushed to the University of Rochester Medical Center emergency room ... surprised to discover that a trendy tea derived from the kava ... reported the case study, believed to be the first of its ... Emergency Medicine . They described it as a cautionary ...
    ... viral load and co-infection with human immunodeficiency virus (HIV) ... of the hepatitis C virus (HCV-VT). A variation in ... the spontaneous clearance of HCV genotype-1 among infected children. ... did not increase risk of HCV-VT in this study. ...
    ... TUESDAY, April 26 (HealthDay News) -- The increased use of ... rapid angioplasty, has led to a decrease in deaths, a ... Swedish coronary care registry on more than 61,000 patients who ... as STEMI between 1996 and 2007. During those 12 ...
    Cached Medicine News:Health News:Get a whiff of this: Low-cost sensor can diagnose bacterial infections 2Health News:Get a whiff of this: Low-cost sensor can diagnose bacterial infections 3Health News:Researchers Describe Gene Activity in Living Cells 2Health News:Anxiety's on the Menu for People With Food Allergies 2Health News:Anxiety's on the Menu for People With Food Allergies 3Health News:Medical sleuthing linked muscle, kidney problems to kava tea 2Health News:Medical sleuthing linked muscle, kidney problems to kava tea 3Health News:Severity of hepatitis C and HIV co-infection in mothers contribute to HCV transmission to child 2Health News:Evidence-Based Heart Attack Care Reduces Deaths: Study 2Health News:Evidence-Based Heart Attack Care Reduces Deaths: Study 3
    Latex-enhanced immunoturbidimetric assay for the quantitative in vitro determination of C-reactive protein in serum and plasma...
    Latex agglutination slide test for the qualitative and semi-quantitative in vitro determination of CRP in serum....
    For the quantitative in vitro determination of Uric Acid in serum, plasma and urine...
    For the quantitative in vitro determination of Apolipoprotein B in human serum...
    Medicine Products: